1541.HK
Price:
$6.38
Market Cap:
$2.25B
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positi...[Read more]
Industry
Biotechnology
IPO Date
2023-09-05
Stock Exchange
HKSE
Ticker
1541.HK
According to ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.72. This represents a change of -41.89% compared to the average of -11.56 of the last 4 quarters.
The mean historical PE Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. over the last ten years is -13.92. The current -6.72 PE Ratio has changed 4.73% with respect to the historical average. Over the past ten years (40 quarters), 1541.HK's PE Ratio was at its highest in in the March 2022 quarter at 0. The PE Ratio was at its lowest in in the September 2023 quarter at -25.47.
Average
-13.92
Median
-12.03
Minimum
-25.83
Maximum
-5.79
Discovering the peaks and valleys of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 97.24%
Maximum Annual PE Ratio = -5.79
Minimum Annual Increase = -77.60%
Minimum Annual PE Ratio = -25.83
Year | PE Ratio | Change |
---|---|---|
2024 | -5.79 | -77.60% |
2023 | -25.83 | 61.78% |
2022 | -15.97 | 97.24% |
The current PE Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-15.86
5-year avg
-13.92
10-year avg
-13.92
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmuneOnco Biopharmaceuticals (Shanghai) Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImmuneOnco Biopharmaceuticals (Shanghai) Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s PE Ratio?
How is the PE Ratio calculated for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)?
What is the highest PE Ratio for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)?
What is the 3-year average PE Ratio for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)?
What is the 5-year average PE Ratio for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)?
How does the current PE Ratio for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) compare to its historical average?